Prulifloxacin nano spheres and preparation method thereof

A technology of prulifloxacin and nanospheres, which is applied in the field of preparation of prulifloxacin nanospheres, can solve the problems of prulifloxacin being insoluble in water and poor bioavailability, and overcome chemical and physiological instability Enhanced stability, improved stability, and increased in vitro stability
CN102274180BActive Publication Date: 2013-04-17NANJING ZENKOM PHARMA
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
NANJING ZENKOM PHARMA
Publication Date
2013-04-17

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses prulifloxacin nano spheres and a preparation method thereof. The nano spheres solve the problems that prulifloxacin is not dissolved in water and has poor bioavailability and the like. The diameter of the nano spheres is below 100 nanometers, the sterile purpose can be fulfilled by filtering and removing bacteria, the stability is increased, the in vivo circular degradation speed is delayed, the stress effect is reduced, and the medicinal effect is improved. The prulifloxacin nano spheres consist of the following components by weight: 0.2 to 1.5 grams of prulifloxacin,15 to 45 grams of oil for injection, 10 to 25 grams of emulsifier, 10 to 25 grams of co-emulsifier, 8 to 13 grams of glycerol and 450 to 500 grams of water for injection.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of pharmaceutical manufacturing and relates to a new dosage form of prulifloxacin, in particular to a preparation method and application of prulifloxacin nanospheres. Background technique

[0002] Prulifloxacin is a third-generation fluoroquinolone spectrum antibacterial drug jointly developed by Japan Shinyaku Corporation and Meiji Seika Corporation. It was registered in Japan on October 8, 2002, and went on the market on December 6 of the same year.

[0003] 1. Pharmacology and Toxicology

[0004] Prulifloxacin is a lipophilic prodrug of the thiabutidine quinoline carboxylic acid derivative NM394 (AF3013). After oral administration, NM441 is easily absorbed from the intestinal tract, and is hydrolyzed into the active form NM394 in vivo to exert a broad-spectrum antibacterial effect. Belonging to quinolone antibiotics, it inhibits bacterial DNA synthesis by inhibiting the activity of bacterial DNA topoisomerase II ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More